Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COGT NASDAQ:RAPT NASDAQ:STOK NASDAQ:VCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOGTCogent Biosciences$14.81-0.3%$13.58$3.72▼$17.15$1.68B0.31.97 million shs3.03 million shsRAPTRapt Therapeutics$29.89-0.4%$19.90$5.67▼$42.39$493.22M0.23169,721 shs346,681 shsSTOKStoke Therapeutics$32.13-1.2%$24.20$5.35▼$38.69$1.76B1.24892,052 shs302,108 shsVCELVericel$36.58+0.4%$33.67$29.24▼$63.00$1.85B1.39556,986 shs238,366 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOGTCogent Biosciences-6.37%-10.38%+18.71%+21.82%+21.32%RAPTRapt Therapeutics-10.53%+10.99%+49.03%+137.15%+109.50%STOKStoke Therapeutics-6.23%-8.65%+42.32%+140.71%+159.74%VCELVericel-0.05%+8.45%+14.52%-8.28%-12.91%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOGTCogent Biosciences$14.81-0.3%$13.58$3.72▼$17.15$1.68B0.31.97 million shs3.03 million shsRAPTRapt Therapeutics$29.89-0.4%$19.90$5.67▼$42.39$493.22M0.23169,721 shs346,681 shsSTOKStoke Therapeutics$32.13-1.2%$24.20$5.35▼$38.69$1.76B1.24892,052 shs302,108 shsVCELVericel$36.58+0.4%$33.67$29.24▼$63.00$1.85B1.39556,986 shs238,366 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOGTCogent Biosciences-6.37%-10.38%+18.71%+21.82%+21.32%RAPTRapt Therapeutics-10.53%+10.99%+49.03%+137.15%+109.50%STOKStoke Therapeutics-6.23%-8.65%+42.32%+140.71%+159.74%VCELVericel-0.05%+8.45%+14.52%-8.28%-12.91%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOGTCogent Biosciences 2.71Moderate Buy$20.8340.72% UpsideRAPTRapt Therapeutics 2.67Moderate Buy$33.0010.42% UpsideSTOKStoke Therapeutics 2.88Moderate Buy$30.83-4.04% DownsideVCELVericel 2.71Moderate Buy$58.4059.67% UpsideCurrent Analyst Ratings BreakdownLatest RAPT, COGT, STOK, and VCEL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/21/2025RAPTRapt TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$38.00 ➝ $48.0010/21/2025COGTCogent BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$30.00 ➝ $44.0010/21/2025RAPTRapt TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$35.00 ➝ $58.0010/20/2025RAPTRapt TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Overweight$13.00 ➝ $55.0010/15/2025COGTCogent BiosciencesStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageHold$16.0010/15/2025VCELVericelTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$46.00 ➝ $41.0010/14/2025VCELVericelZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/13/2025RAPTRapt TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetEqual Weight ➝ Overweight$35.0010/13/2025RAPTRapt TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageEqual Weight ➝ Overweight$35.0010/13/2025STOKStoke TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$28.00 ➝ $39.0010/10/2025STOKStoke TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$22.00 ➝ $35.00(Data available from 10/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOGTCogent BiosciencesN/AN/AN/AN/A$1.32 per shareN/ARAPTRapt Therapeutics$1.53M323.07N/AN/A$11.51 per share2.60STOKStoke Therapeutics$36.56M48.16N/AN/A$4.32 per share7.44VCELVericel$237.22M7.78$0.31 per share116.64$5.92 per share6.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOGTCogent Biosciences-$255.86M-$1.78N/AN/AN/AN/A-223.82%-89.44%11/11/2025 (Estimated)RAPTRapt Therapeutics-$129.87M-$14.17N/AN/AN/AN/A-67.92%-59.59%11/11/2025 (Estimated)STOKStoke Therapeutics-$88.98M$0.8537.80N/AN/A26.25%18.32%15.48%11/4/2025 (Estimated)VCELVericel$10.36M$0.12305.1883.13N/A2.85%2.47%1.69%11/6/2025 (Estimated)Latest RAPT, COGT, STOK, and VCEL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025COGTCogent Biosciences-$0.54N/AN/AN/AN/AN/A11/11/2025Q3 2025RAPTRapt Therapeutics-$0.84N/AN/AN/AN/AN/A11/6/2025Q3 2025VCELVericel-$0.02N/AN/AN/A$64.57 millionN/A11/4/2025Q3 2025STOKStoke Therapeutics-$0.56N/AN/AN/AN/AN/A8/12/2025Q2 2025STOKStoke Therapeutics-$0.57-$0.40+$0.17-$0.40$31.51 million$13.82 million8/7/2025Q2 2025RAPTRapt Therapeutics-$0.61-$0.65-$0.04-$0.65N/AN/A8/5/2025Q2 2025COGTCogent Biosciences-$0.55-$0.53+$0.02-$0.53N/AN/A7/31/2025Q2 2025VCELVericel-$0.04-$0.01+$0.03-$0.01$64.61 million$63.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOGTCogent BiosciencesN/AN/AN/AN/AN/ARAPTRapt TherapeuticsN/AN/AN/AN/AN/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/AVCELVericelN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOGTCogent BiosciencesN/A4.194.19RAPTRapt TherapeuticsN/A13.2513.25STOKStoke TherapeuticsN/A6.986.98VCELVericelN/A4.974.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOGTCogent BiosciencesN/ARAPTRapt Therapeutics99.09%STOKStoke TherapeuticsN/AVCELVericelN/AInsider OwnershipCompanyInsider OwnershipCOGTCogent Biosciences7.29%RAPTRapt Therapeutics2.36%STOKStoke Therapeutics9.50%VCELVericel5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOGTCogent Biosciences80113.86 million105.56 millionOptionableRAPTRapt Therapeutics8016.54 million16.15 millionOptionableSTOKStoke Therapeutics10054.80 million49.59 millionOptionableVCELVericel30050.46 million47.84 millionOptionableRAPT, COGT, STOK, and VCEL HeadlinesRecent News About These CompaniesHere’s Why Vericel Corporation (VCEL) Underperformed in Q3October 22 at 10:34 PM | msn.comVericel Corporation $VCEL Shares Purchased by Mutual of America Capital Management LLCOctober 21 at 4:40 AM | marketbeat.comTruist Lowers PT on Vericel Corporation (VCEL) to $41 From $46October 20 at 11:30 PM | insidermonkey.comConestoga Capital Advisors LLC Buys 401,990 Shares of Vericel Corporation $VCELOctober 20 at 3:33 AM | marketbeat.comWilliam Blair Investment Management LLC Sells 123,021 Shares of Vericel Corporation $VCELOctober 19, 2025 | marketbeat.comVericel (NASDAQ:VCEL) Trading Up 5.6% - Here's What HappenedOctober 17, 2025 | marketbeat.comVericel (NASDAQ:VCEL) Upgraded by Zacks Research to "Strong-Buy" RatingOctober 16, 2025 | marketbeat.comAllspring Global Investments Holdings LLC Acquires 610,045 Shares of Vericel Corporation $VCELOctober 16, 2025 | marketbeat.comAberdeen Group plc Buys Shares of 209,217 Vericel Corporation $VCELOctober 16, 2025 | marketbeat.comVericel price target lowered to $41 from $46 at TruistOctober 16, 2025 | msn.comTruist Securities Maintains Vericel (VCEL) Buy RecommendationOctober 16, 2025 | msn.comLeerink Partnrs Has Pessimistic View of Vericel Q4 EarningsOctober 15, 2025 | marketbeat.comVericel Corporation (NASDAQ:VCEL) Given Consensus Recommendation of "Moderate Buy" by BrokeragesOctober 15, 2025 | americanbankingnews.comVericel Corporation (NASDAQ:VCEL) Receives Consensus Rating of "Moderate Buy" from AnalystsOctober 10, 2025 | marketbeat.comVericel (NASDAQ:VCEL) Receives "Sell (D+)" Rating from Weiss RatingsOctober 9, 2025 | marketbeat.comVericel Corporation $VCEL Shares Purchased by PFG Investments LLCOctober 4, 2025 | marketbeat.comCanaccord Genuity Keeps Their Buy Rating on Vericel (VCEL)September 26, 2025 | theglobeandmail.comVericel Corporation $VCEL Shares Acquired by Congress Asset Management Co.September 26, 2025 | marketbeat.comVericel (NASDAQ:VCEL) Hits New 12-Month Low - Time to Sell?September 25, 2025 | marketbeat.comKopp Family Office LLC Sells 8,554 Shares of Vericel Corporation $VCELSeptember 24, 2025 | marketbeat.comVoya Investment Management LLC Purchases 10,048 Shares of Vericel Corporation $VCELSeptember 24, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRAPT, COGT, STOK, and VCEL Company DescriptionsCogent Biosciences NASDAQ:COGT$14.80 -0.05 (-0.30%) As of 01:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Rapt Therapeutics NASDAQ:RAPT$29.88 -0.12 (-0.38%) As of 01:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb CompanyStoke Therapeutics NASDAQ:STOK$32.13 -0.39 (-1.20%) As of 01:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.Vericel NASDAQ:VCEL$36.58 +0.15 (+0.40%) As of 01:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Is Oracle’s AI Rally Over? Wall Street Thinks ORCL Could Hit $400 3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys The Best AI for Picking Stocks, Ranked by Performance Will D-Wave's European Expansion Keep Fueling the Rally? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
